Ternary mixture formulations

Abstract

The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly-water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substance's dissolution.

The claimed invention is: 
     
         1 . A process for making a free-flowing powder pharmaceutical formulation comprising the steps of:
 (a) dissolving a phospholipid component, a poorly water-soluble drug substance component, and a surfactant component in a water partially miscible or water non-miscible solvent or combination of partially miscible or water non-miscible solvents to form a first solution;   (b) dissolving a solubilizing aid component in water to form a second solution;   (c) adding a water-miscible solvent to the second solution to form a third solution;   (d) combining the first solution and with the third solution to form a clear homogenous solution; and   (e) producing a free flowing powder having a homogenous mixture of the phospholipid component, the poorly water-soluble drug substance component, the surfactant component, and the solubilizing aid component by spray drying the clear homogenous solution, precipitating the clear homogenous solution, or coating the clear homogenous solution onto a surface of an inert substrate.   
     
     
         2 . A process according to  claim 1 , wherein the phospholipid component comprises soy phosphatidyl choline, egg phosphatidyl choline, dimyristoyl-phosphocholine, dimyristoyl-phosphoglycerol, distearoyl-phosphatidylcholine, distearoyl-phosphatidylglycerol, or Dipalmitoyl-phosphocholine, or a combination thereof. 
     
     
         3 . A process according to  claim 1 , wherein at least one poorly water-soluble active agent is requires 100 to 1,000 parts of water to one part drug substance to achieve solubility. 
     
     
         4 . A process according to  claim 1 , wherein the surfactant component comprises Vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), a polyoxylglyceride, a poloxamer, poloxamine, a sorbitan oleate, a polyoxyethylene stearate, a nonionic polyoxyethylene, sodium lauryl sulfate (SLS), cetyl trimethylammonium bromide (CTAB), polysorbate 20, polysorbate 40, or polysorbate 80, or a combination thereof. 
     
     
         5 . A process according to  claim 1 , wherein at least one water non-miscible or partially miscible solvent selected from chloroform, dichloromethane, ethyl acetate, ethyl methyl ketone, diethyl ether or a combination thereof. 
     
     
         6 . A process according to  claim 1 , wherein at least one water-miscible solvent is selected from ethanol, methanol, acetone, acetonitrile, benzyl alcohol, isopropyl alcohol, dimethyl sulfoxide or a combination thereof. 
     
     
         7 . A process according to  claim 1 , wherein the solubilizing aid component comprises lactose, mannitol, sucrose, glucose, polydextrose, a cyclodextrin, polyvinyl pyrrolidone, polyvinyl alcohol, poly ethyleneglycol, or amino alkyl methacrylate copolymers, or a combination thereof. 
     
     
         8 . A process according to  claim 1 , wherein the solubilizing aid component constitutes from 59% to 76% of the total combined weights of the phospholipid, poorly water-soluble drug substance, surfactant, and solubilizing aid components.